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Tumor progression locus-2 (Tpl2) kinase is a major inflammatory
mediator in immune cell types recently found to be genetically
associated with inflammatory bowel diseases (IBDs). Here we show
that Tpl2 may exert a dominant homeostatic rather than inflamma-
tory function in the intestine mediated specifically by subepithelial
intestinal myofibroblasts (IMFs). Mice with complete or IMF-specific
Tpl2 ablation are highly susceptible to epithelial injury-induced co-
litis showing impaired compensatory proliferation in crypts and
extensive ulcerations without significant changes in inflammatory
responses. Following epithelial injury, IMFs sense innate or inflam-
matory signals and activate, via Tpl2, the cyclooxygenase-2 (Cox-2)-
prostaglandin E2 (PGE2) pathway, which we show here to be es-
sential for the epithelial homeostatic response. Exogenous PGE2
administration rescues mice with complete or IMF-specific Tpl2 ab-
lation from defects in crypt function and susceptibility to colitis. We
also show that Tpl2 expression is decreased in IMFs isolated from
the inflamed ileum of IBD patients indicating that Tpl2 function in
IMFs may be highly relevant to human disease. The IMF-mediated
mechanism we propose also involves the IBD-associated genes
IL1R1, MAPK1, and the PGE2 receptor-encoding PTGER4. Our
results establish a previously unidentified myofibroblast-specific
innate pathway that regulates intestinal homeostasis and may un-
derlie IBD susceptibility in humans.
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Inflammatory bowel diseases (IBDs), encompassing Crohn’sdisease and ulcerative colitis, are chronic inflammatory dis-
orders of the gastrointestinal tract that develop from a complex
and largely unknown etiology (1). Recent genome-wide associ-
ation studies (GWAS) for IBD showed significant association
with SNP rs1042058 in mitogen-activated protein kinase kinase
kinase 8 (MAP3K8) gene (2) which encodes tumor progression
locus-2 (Tpl2) kinase (SI Appendix, Fig. S1 A and B). Molecu-
larly, Tpl2 is known to bind to NF-ĸB1-p105 in a stabilized but
inactive form (3) and, when activated, is released to phosphor-
ylate the major immediate targets MEK1/2 activating mainly the
ERK pathway and downstream inflammatory mediators (3). The
NFKB1 gene is also genetically associated with IBD in GWAS
(2), highlighting the relevance of this pathway to human disease.
Tpl2−/− mice show defective TNF expression in response to LPS
(4), high susceptibility to Listeria due to defective IL-1β expres-
sion (5), and impaired Th1 responses (6). Tpl2 also mediates
pathogenesis in the TNF-driven and T-cell–mediated TnfΔARE
mouse model of Crohn’s-like IBD, indicating a potential path-
ogenic relevance of this pathway in specific contexts (7). Due to
these proinflammatory functions, established mainly in cells of
hematopoietic origin, Tpl2 is considered to be an appealing
pharmacological target for the treatment of IBD and other in-
flammatory diseases (3, 8).
The genetic association of MAP3K8 with IBD, however, may
indicate unknown homeostatic functions of Tpl2 in the intestine.
GWAS results provide insights into the complexity underlying
MAP3K8 association because along with NFKB1, an additional
25 genes functionally related to Tpl2 are genetically associated
with IBD (2). These functional interactions can be clustered in
a wide spectrum of cell types and potential mechanisms (SI
Appendix, Fig. S2 A and B and Table S1). Indeed, Tpl2 functions
in many different cell types downstream of receptors such as
CD40 (9), CD3/CD28 (10), TNFRI (11), IL-1R (11), NOD2 (5),
or TLR4 (4). Notably, these pathways may have opposing roles
in intestinal homeostasis and IBD; for example, contrasting ho-
meostatic and epithelial cell death-promoting roles have been
suggested for TLR4 and TNFRI, respectively (12, 13). A cell-
specific approach is therefore required for detailed mechanistic
understanding of the role of Tpl2 in IBD and effective thera-
peutic design.
Here, studying the role of Tpl2 in intestinal homeostasis and
IBD pathogenesis in a cell-specific manner, we identify a myo-
fibroblast-specific Tpl2-Cox-2-PGE2 pathway which plays a
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homeostatic role in the gut by promoting the compensatory
proliferative response of the epithelium upon injury. This
mechanism highlights the dominant role of IMFs in regulating
epithelial homeostasis and also provides a possible explana-
tion for the MAP3K8 association with IBD (see Fig. 8).
Results
Tpl2 Plays a Homeostatic Role in the Gut Following Epithelial Injury.
To study the cell-specific functions of Tpl2 we generated Tpl2
conditional (floxed, Tpl2FL/FL) and complete knockout mice
(defloxed, Tpl2D/D) as described in Materials and Methods and SI
Appendix, Fig. S3. To investigate the role of Tpl2 in intestinal
homeostasis and IBD pathogenesis we used the DSS-induced co-
litis model which is based on epithelial barrier disruption involving
mainly innate immune responses (14) and activation of epithelial
repair mechanisms. We observed that Tpl2D/D mice are highly
susceptible to DSS-induced colitis exhibiting significantly increased
weight loss, disease activity index, and lethality and reduced colon
length compared with normal littermate controls (Fig. 1 A–D).
Tpl2D/D mice also display exacerbated histopathological features of
colitis with increased loss of Goblet cells, extensive loss of crypts,
and focal ulceration at an early time point (Fig. 1 E–G), pro-
gressing later to severe and widely spread ulceration (Fig. 1 E and
F). Tpl2D/D mice show throughout the DSS-induced colitis protocol
significantly increased tissue damage histological score as reflected
in loss of crypts and ulceration (Fig. 1H) but similar inflammation
scores compared with WT controls (Fig. 1H). These results show
that Tpl2 plays an unexpected homeostatic role in the intestine
following epithelial injury.
Tpl2 Is Dispensable for Inflammatory Infiltration but Critically
Implicated in Mechanisms of Epithelial Homeostasis upon Epithelial
Injury. FACS analysis in isolated colonic lamina propria and
mesenteric lymph node populations showed similar infiltrations
of macrophages and granulocytes in Tpl2D/D and WT mice early
upon epithelial injury (Fig. 2 A and B and SI Appendix, Fig. S4B).
In addition, no differences were observed in myeloperoxidase
activity (Fig. 2C) or in the expression of several inflammatory
cytokines and chemokines in the colons of these mice (SI Ap-
pendix, Fig. S4 C and D). Similar results in terms of inflammatory
activation and myeloperoxidase activity were obtained at a later
time point (SI Appendix, Fig. S5). Examination of immune and
cytokine secretion pathways in which Tpl2 has been demonstrated
to be involved in vivo (6, 15, 16) showed that Th1 and Th17
responses, IL-10 secretion from CD4+ T cells, and IFN-γ secretion
from CD8+ T cells were similar in the lamina propria of Tpl2D/D
and WT mice (SI Appendix, Fig. S4A). This observation is pos-
sibly related to the predominance of innate pathways in the DSS
model (14). The above results suggest that in the context of DSS
colitis, Tpl2 is dispensable for the development of inflamma-
tory responses. On the other hand, the accelerated loss of crypts
in DSS-treated Tpl2D/D mice suggests a possible involvement of
Tpl2 in the mechanisms of epithelial homeostasis including ep-
ithelial proliferation, migration, differentiation, and cell death.
TUNEL assays in the colon of DSS-treated Tpl2D/D and WT
control mice showed a similar extent of spontaneous epithelial
apoptosis (SI Appendix, Fig. S6 A and B). Because aberrant in-
testinal epithelial cell (IEC) death requires IEC sensitization to
TNF (13, 17) and Tpl2 mediates TNFRI signaling (3), we also
performed TUNEL assays in the intestine of TNF-injected Tpl2D/D
and WT mice and excluded an implication of Tpl2 in TNF-induced
Fig. 1. Tpl2 deficient mice are highly susceptible to dextran sodium sulfate (DSS)-induced colitis. (A–C) Tpl2D/D (n = 32) and WT control mice (n = 47) were
treated with 2.5% DSS in five independent experiments. Tpl2D/D mice showed (A) increased weight loss, (B) increased disease activity index, and (C) increased
lethality (P = 0.00258; Gehan–Wilcoxon test) compared with WT controls. (D) Tpl2D/D mice (n = 19) showed reduced colon length on experimental day
8 compared with WT control mice (n = 33) in three independent experiments. (E) Methylene blue staining of colon whole mounts from DSS-treated Tpl2D/D
and WT control mice on days 3 and 8. Tpl2D/D mice show early loss of crypts and focal ulceration on day 3, progressing later to widespread ulceration.
(Magnification: 100×.) (F) Tpl2D/D mice show early loss of crypts on day 3 progressing later to complete loss of crypts and extensive ulceration on day 8. H&E-
stained colon sections. (Scale bars: 100 μm.) (G) Early loss of Goblet cells in Tpl2D/D mice as shown by periodic acid-Schiff staining. (Scale bars: 100 μm.) (H)
Histopathological analysis of DSS-treated Tpl2D/D and WT control mice early on day 3 (n = 5 and 6, respectively), on day 5 (n = 7 and 9), and late on day 8 (n =
11 and 18). All data shown represent mean ± SEM. Statistical significance was calculated with Student t test, Welch’s t test, or Mann–Whitney test (*P < 0.05;
**P < 0.01; ***P < 0.001; ns, nonsignificant).
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IEC death (SI Appendix, Fig. S6C). In addition, 9-mo-old Tpl2D/D
mice have normal Paneth and Goblet cell populations in the ileum
and the colon, indicating that there are no defects in mechanisms
of epithelial differentiation (SI Appendix, Fig. S7). On the other
hand, loss of crypts and ulceration may result from defects in
mechanisms of compensatory epithelial proliferation. Notably,
DSS-treated Tpl2D/D mice show reduced expression of Sox9 in the
colon (Fig. 2D), which is a well-established crypt progenitor/stem
cell marker (18). DSS treatment leads to an early reduction of
Sox9+ cells in the basal part of colonic crypts in WT mice. This
reduction in Sox9+ cells is significantly enhanced in Tpl2D/D mice
leading to areas with severe depletion of Sox9+ cells (Fig. 2 E and F).
To examine whether this reduction of Sox9+ cells reflects early pro-
liferation defects, we monitored epithelial proliferation by BrdU-
pulse administration experiments on experimental day 3. These
experiments showed significantly reduced cells incorporating
BrdU (cells in S-phase) in the crypts of Tpl2D/D mice compared
with WT littermates (Fig. 2G). A defect in epithelial cell pro-
liferation was even more prominent later on day 8 (Fig. 2H),
resulting in a vast depletion of the epithelial monolayer in Tpl2D/D
mice (Fig. 2I). These results suggest a physiologically relevant
implication of Tpl2 in mechanisms of compensatory epithelial
proliferation in response to injury. This function is similar to that
of Myd88 and TLR4, which are upstream activators of Tpl2 and
also promote compensatory proliferation in the intestinal epi-
thelium protecting from experimental colitis (19, 20) through
still unidentified cellular mechanisms. These results raised the
question on the specific cellular and molecular pathways through
which Tpl2 promotes compensatory proliferation.
Conditional Inactivation of Tpl2 Reveals a Critical Homeostatic Role of
Intestinal Myofibroblasts in Epithelial Response to Injury. To examine
the cellular pathways mediating the homeostatic role of Tpl2 in the
colon we generated mice bearing myeloid lineage-specific Tpl2
ablation (Tpl2MYEL-KO) using LysMCre (21) mice (SI Appendix, Fig.
S8 A–C) and mice bearing IEC-specific Tpl2 ablation (Tpl2IEC-KO)
using VillinCre (22) mice (SI Appendix, Fig. S9 A and B). Both
Tpl2MYEL-KO mice and Tpl2IEC-KO mice showed similar responses
to DSS-induced epithelial injury compared with the respective
Tpl2FL/FL littermate controls (thereafter referred as Tpl2FL mice) in
terms of weight loss, disease activity index, colon length, and his-
tological features of colitis (Fig. 3 A–F and SI Appendix, Figs S8 and
S9), arguing against a homeostatic role of Tpl2 through macro-
phages, granulocytes, or IECs.
Intestinal subepithelial myofibroblasts (IMFs) are mesenchymal
cells which underlie the epithelium in close proximity to the crypts,
where they participate in stem cell niche formation and de-
velopmental processes (23–26). To examine whether the reduction
of Sox9+ cells and the defective epithelial proliferation in Tpl2D/D
mice result from a mesenchymal cell-mediated mechanism, we used
ColVICre transgenic mice, which express Cre recombinase in IMFs
(27), to generate ColVICreTpl2FL/FL mice (Tpl2IMF-KO) bearing
inactivation of Tpl2 in IMFs as shown previously (28). Remarkably,
DSS administration in Tpl2IMF-KO mice led to an exacerbated colitis
phenotype characterized by significantly increased weight loss,
Fig. 2. Tpl2 is implicated in the mechanisms of epithelial homeostasis upon DSS treatment but is dispensable for inflammatory infiltration. (A) Quantification
of isolated lamina propria cells in Tpl2D/D mice (n = 4) and WT controls (n = 4) on day 3.5 upon DSS treatment shows similar inflammatory infiltration. In-
dicative of two independent experiments. (B) Quantification of macrophages (CD11b+Gr1low) and granulocytes (CD11b+Gr1hi) in the lamina propria by flow
cytometry analysis. (C) Tpl2D/D mice (n = 5) and WT controls (n = 5) show similar myeloperoxidase activity in the colon on day 3 of DSS treatment. (D) Sox9
protein levels are reduced in the colons of Tpl2D/D mice on day 8 of DSS treatment compared with DSS-treated WT controls and untreated mice. (E)
Quantification of Sox9+ cells in the crypts of untreated and DSS-treated Tpl2D/D and WT control mice by immunostaining as displayed in F. Sox9+ cells in the
crypts are reduced following DSS treatment, and Tpl2 deletion significantly enhances their loss. (F) Immunostaining for Sox9 in Tpl2D/D and WT control mice,
untreated or DSS-treated for 3 d (n = 3–4 each), reveals crypts with markedly reduced Sox9+ cells in Tpl2D/D mice. (Scale bars: 100 μm.) (G) Epithelial pro-
liferation in Tpl2D/D mice (n = 5) and WT controls (n = 6) on day 3 of DSS treatment assessed by BrdU incorporation in the crypts. Tpl2D/D mice show sig-
nificantly reduced numbers of BrdU-incorporating cells. (Scale bars: 100 μm.) (H) BrdU incorporation experiments on day 8 of DSS treatment show loss of alive
crypts in Tpl2D/D mice (n = 5) in contrast to WT controls (n = 5) in which the crypts show proliferative activity. (I) Tpl2D/D mice (n = 3) show extensive epithelial
cell depletion on day 8 shown by E-cadherin immunostaining. Nuclei are stained with DAPI. (Magnification: 200×.) All data shown represent mean ± SEM.
Statistical significance was calculated with Student t test or Mann–Whitney test (***P < 0.001; **P < 0.01; ns, nonsignificant).
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disease activity index, and lethality (Fig. 3 G–I) and reduced
colon length (Fig. 3J) compared with Tpl2FL controls. Histo-
pathological analysis showed that Tpl2IMF-KO mice display simi-
lar inflammation but significantly increased tissue damage score
with early loss of crypts on experimental day 3 progressing to
extensive ulceration on experimental day 8 (Fig. 3 K and L).
These results establish a phenotype similar to that observed in
Tpl2D/D mice, demonstrating that selective inactivation of Tpl2 in
IMFs is sufficient to confer increased susceptibility to DSS-in-
duced colitis. BrdU-pulse administration experiments showed
a defective proliferative response to injury in the epithelium of
Tpl2IMF-KO mice at both an early and a late time point during
DSS treatment (Fig. 3M) associated with extensive epithelial cell
depletion (Fig. 3N). These results show that IMFs protect the
colonic epithelium following DSS-induced injury through the
activation of the Tpl2 pathway, suggesting a previously unknown
dominant role for this cell type in the maintenance of epithelial
homeostasis. The homeostatic role of IMFs via Tpl2 upon intestinal
damage was further validated in a second experimental colitis
model; 2,4,6-trinitro benzene sulfonic acid (TNBS)-induced co-
litis. Tpl2IMF-KO mice subjected to TNBS-induced colitis show an
exacerbated pathology characterized by increased weight loss,
loss of crypts, and ulceration, even also transmural ulceration
and necrosis, reflected as high tissue damage histological score
(SI Appendix, Fig. S10).
To examine the distribution of intestinal myofibroblasts in the
colon upon epithelial injury we treated WT mice with DSS and
performed immunostainings against alpha smooth muscle actin
(α-SMA), a microfilament protein expressed by myofibroblasts
but also by pericytes, muscularis mucosae smooth muscle cells,
and lymphatic lacteal-associated smooth muscle cells of the
lamina propria (23). We observed that the network of α-SMA+
mesencymal cells of the lamina propria is reorganized in the
colon of DSS-treated mice in association with tissue damage
progression. An accelerated redistribution of α-SMA+ cells is
observed in Tpl2D/D DSS-treated mice in the early lesions oc-
curring upon DSS injury (SI Appendix, Fig. S11).
Fig. 3. Tpl2 ablation in intestinal myofibroblasts, but not in myeloid lineage or intestinal epithelial cells, is sufficient to confer increased susceptibility to
DSS-induced colitis. (A–C) Myeloid-specific Tpl2MYEL-KO (n = 14) and Tpl2FL control mice (n = 16) treated with 2.5% DSS in two independent experiments show
similar weight loss, colon length on day 8, and histopathological features. (D–F) Epithelial-specific Tpl2IEC-KO (n = 17) and Tpl2FL control mice (n = 18) treated
with 2.5% DSS in three independent experiments show similar weight loss, colon length on day 8, and histopathological features. (G–L) Tpl2IMF-KO (n = 33) and
Tpl2FL control mice (n = 39) were treated with 2.5% DSS in six independent experiments. Tpl2IMF-KO mice show increased weight loss (G), disease activity index
(H), and lethality (I) (P = 0.02891; Gehan–Wilcoxon test). (J) Reduced colon length on day 8 in Tpl2IMF-KOmice (n = 21) compared with Tpl2FL controls (n = 24) in
three independent experiments. (K) Inflammation and tissue damage scores in DSS-treated Tpl2IMF-KO mice compared with Tpl2FL controls early on day
3 (n = 4 and 5, respectively), on day 5 (n = 6 and 5), and late on day 8 (n = 18 and 23). (L) Tpl2IMF-KO mice show early loss of crypts progressing to complete loss
of crypts and extensive ulceration. H&E-stained sections. (Scale bars: 100 μm.) (M) Tpl2IMF-KO mice show reduced proliferation in the crypts monitored by BrdU
incorporation (scale bars: 100 μm), and (N) extensive epithelial cell depletion on day 8 by E-cadherin immunostaining. (Magnification: 200×.) All data rep-
resent mean ± SEM. Student t test or Mann–Whitney test (*P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant).
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Molecular Profiling of Tpl2 Deficient Intestinal Myofibroblasts and
Further Analyses Show Deregulation of Arachidonic Acid Meta-
bolism and Prostaglandin Production Pathways. To examine the
molecular pathways underlying the homeostatic function of Tpl2
in myofibroblasts we isolated IMFs from Tpl2D/D and WT control
mice and analyzed the signaling pathways and downstream mo-
lecular targets that may be affected. Tpl2 in IMFs is not re-
quired for ERK activation upon stimulation with IL-18 or
Fig. 4. Tpl2 in intestinal myofibroblasts mediates MAPK activation upon innate or inflammatory stimulation and is implicated in the activation of the Cox-2
pathway and arachidonic acid metabolism. (A and B) Western blots for phospho-ERK (p-ERK) and phospho-JNK (p-JNK) in IMFs isolated from Tpl2D/D and WT
mice stimulated with IL-1β or LPS. (C and D) Gene expression profiling was performed by RNA-seq in primary nonstimulated IMFs isolated from Tpl2D/D and WT
mice in four independent experiments (A to D). (C) Top and bottom 20 consistently deregulated genes are presented in a heat map. (D) Gene set enrichment
analysis shows consistent enrichment of five KEGG pathways in genes deregulated in Tpl2D/D IMFs. (E) Tpl2 in IMFs partially mediates the induction of IL-1β or
LPS-driven gene networks overlapping with the IBD-GWAS subnetwork downstream of IL-1β. Hierarchical clustering of genes consistently deregulated upon
stimulation of IMFs with IL-1β or LPS in two independent experiments. Genes up-regulated in response to IL-1β or LPS are shown as STRING functional
networks with highlighted genes showing defective up-regulation in Tpl2D/D IMFs and genes genetically associated with IBD in GWAS (2). (F) Western blots for
ΙκB and phospho-CREB (p-CREB) in Tpl2D/D and WT IMFs stimulated with IL-1β or LPS. (G) RT-PCR for Ptgs1 and Ptgs2 gene expression levels in Tpl2D/D and WT
IMFs stimulated with IL-1β or LPS (n = 3 each). (H) Cox-2 protein expression levels were measured by FACS analysis in IMFs stimulated with IL-1β or LPS for 16h
(n = 3 each). Values represent relative mean fluorescence intensity (MFI) based on untreated controls. (I) Tpl2 is required for optimal Cox-2 up-regulation in
IMFs upon stimulation with IL-1β or LPS as shown by Western blot. (J) Ex vivo validation of the Cox-2 pathway deregulation in the absence of Tpl2. Tpl2D/D and
WT control mice (each n = 2 pooled) were treated for 6 d with 2.5% DSS or normal water, and stromal cells of the colon were isolated and cultured for 24 h
without stimulation. Cox-2 protein levels were examined with Western blot. Indicative of two independent experiments. (K) Cox-2–mediated eicosanoids
detected by mass spectrometry in supernatants of IL-1β or LPS-stimulated Tpl2D/D and WT IMFs (n = 4 each). Precursor ion mass (m/z) 297.1530 corresponds to
PGE2 metabolites (13,14-dihydro-tetranor-15-keto-PGE2 and tetranor-PGE1), and m/z 353.2030 corresponds to metabolites downstream of PGH1 and PGH2
(SI Appendix, Methods). Bars represent relative ion intensities compared with untreated controls. All data represent mean ± SEM. Student t test or
Mann–Whitney test (*P < 0.05; **P < 0.01; ***P < 0.001; ns, nonsignificant).
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muramyl dipeptide, a NOD2 ligand (SI Appendix, Fig. S12), but
it is required for ERK and to a less extent JNK activation upon
stimulation with IL-1β (Fig. 4A) or LPS (Fig. 4B), similarly to
its function described in other cell types (3). To gain insights
into pathways mediated by Tpl2 in IMFs, we analyzed by RNA
sequencing the expression profile of primary Tpl2D/D and WT
IMFs, untreated or stimulated with IL-1β or LPS. Analysis of
untreated Tpl2D/D IMFs in four independent experiments
showed consistent deregulation of a subset of ∼40 genes at twofold
expression levels (Fig. 4C). Gene set enrichment analysis per-
formed in these expression data revealed a consistent deregulation
of five KEGG pathways in the absence of Tpl2, namely, retinol
metabolism, cytokine–cytokine receptor interaction, melanoma,
arachidonic acid metabolism, and cell adhesion molecules (Fig.
4D). From genes which are down- or up-regulated in untreated
Tpl2D/D IMFs we computationally inferred transcription factors
which may mediate their activation such as CREB and the myo-
genesis-related Myog and Myod1, respectively (SI Appendix, Fig.
S13). Furthermore, RNA sequencing in IMFs treated with IL-1β
or LPS and functional network analysis of the genes induced
showed that Tpl2 mediates in part the activation of both IL-1β and
LPS-triggered networks (Fig. 4E). Several genes included in the
IL-1β–induced Tpl2-mediated subnetwork, such as Nos2, Cxcl2,
Ccl11, and the transcription factor Fos, are genetically associated
with IBD in GWAS (Fig. 4E). Gene set enrichment analysis
performed in Tpl2D/D IMFs treated with either IL-1β or LPS
showed deregulation of several pathways related to fibroblast re-
sponse to injury such as extracellular matrix, basement membrane,
and wound healing (SI Appendix, Table S2). Computational
analysis of genes up-regulated upon IL-1β or LPS treatment in-
dicated AP1 and NFκB as the major transcription factors induced
by these stimuli in both WT and Tpl2D/D IMFs (SI Appendix, Fig.
S13). Relevant Western blot analysis showed that IκB is degraded
early upon IL-1β and late upon LPS stimulation in both WT and
Tpl2D/D IMFs (Fig. 4F). On the other hand, we verified by Western
blot that Tpl2 mediates CREB activation in response to IL-1β and
at a later time point in response to LPS in IMFs (Fig. 4F). The
above results suggest implication of Tpl2 in multiple IMF functions
and indicate potential pathways in which Tpl2 may be a dominant
mediator with significant role at the level of intestinal physiology.
Among pathways deregulated in Tpl2 deficient IMFs, of par-
ticular interest for the mechanisms of epithelial homeostasis is
arachidonic acid metabolism which involves production of pros-
taglandins by cyclooxygenases. Cox-2 in particular plays a homeo-
static role in the epithelium, highlighted in Cox-2−/− mice which
are highly susceptible to DSS-induced colitis exhibiting defective
Fig. 5. Exogenous dmPGE2 administration concurrently with DSS treatment rescues the exacerbated colitis phenotype of Tpl2
D/D mice and restores epithelial
proliferation and structure. Concurrently with 2.5% DSS treatment, Tpl2D/D (n = 10) and WT (n = 11) mice received i.p. injections of dmPGE2 every 12 h at
a dose of 10 μg/kg of body weight. Control (ctrl) Tpl2D/D (n = 11) and WT (n = 10) mice were similarly injected with saline. Data represent two independent
experiments. (A) dmPGE2 protects Tpl2
D/D mice from increased weight loss observed in control Tpl2D/D mice (statistically compared), although it has no effect
in WT mice. For days 6–8, Kruskal–Wallis P values are 0.0518, 0.0445, and 0.0083, respectively. (B) Colon length on experimental day 8. (C) Histopathological
analysis on day 8. (D) dmPGE2 rescues Tpl2
D/D mice from the extensive loss of crypts and ulceration observed in control Tpl2D/D mice on day 8, although it has
no effect in WT mice. H&E-stained sections. (Scale bars: 100 μm.) (E) dmPGE2 protects Tpl2D/D mice from the defective epithelial proliferation observed in
control Tpl2D/D mice on day 8, although it has no effect in WT mice as shown by BrdU incorporation experiments. (Scale bars: 100 μm.) (F) dmPGE2 protects
Tpl2D/D mice from the epithelial depletion observed in control Tpl2D/D mice on day 8, although it has no effect in WT mice as shown by E-cadherin immu-
nostaining. Nuclei are stained with DAPI. (Magnification: 200×.) Data shown represent mean ± SEM. Student t test, Welch’s t test, or Mann–Whitney test (*P <
0.05; **P < 0.01; ns, nonsignificant).
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epithelial proliferation due to impaired production of PGE2, the
major product of Cox-2 in colon epithelium (29, 30). Hydroxy-
prostaglandin dehydrogenase 15-(NAD) (Hpgd), a negative reg-
ulator of PGE2 (31), is overexpressed in Tpl2 deficient IMFs
(Fig. 4C). Tpl2 in IMFs mediates Cox-2 activation at the protein
level in response to IL-1β and LPS as shown by Western blot and
FACS analyses (Fig. 4 H and I). This effect involves defective
transcriptional activation of the Ptgs2 (Cox-2) gene downstream of
IL-1β (Fig. 4G) in agreement with the role of Tpl2 in the activation
of CREB (Fig. 4F), a transcription factor binding to Ptgs2 promoter
and mediating its transcription (32). Tpl2 deletion does not affect
Ptgs1 (Cox-1) gene expression levels in IMFs (Fig. 4G). To examine
the in vivo relevance of these results we treated Tpl2D/D and WT
control mice with 2.5% DSS or normal drinking water for 6 d and
isolated stromal cells of the colon after epithelial cell depletion to
measure the levels of spontaneous Cox-2 expression. In support of
our in vitro results we observed impaired up-regulation of Cox-2 in
cells isolated from DSS-treated Tpl2D/D mice (Fig. 4J). In agree-
ment with the above-described role of Tpl2 in Cox-2 activation,
Tpl2D/D IMFs stimulated with IL-1β or LPS show defective se-
cretion of Cox-2–mediated eicosanoids, namely, PGE2 metabolites
and prostanoids downstream of PGH1 and PGH2, as analyzed by
mass spectrometry (Fig. 4K). To specifically examine the role of
Cox-2 in IMFs upon epithelial injury in vivo we generated
Cox-2IMF-KO mice crossing cox-2 conditional knockout mice
(33) with ColVICre (27) mice. Cox-2IMF-KO mice treated with
DSS showed significantly increased weight loss in the early phase
of the protocol, on days 4 and 5, but not later on, indicating
a homeostatic role of Cox-2 in IMFs early upon epithelial injury
(SI Appendix, Fig. S14). Of note, Cox-2 in myeloid and endo-
thelial cells also exerts a homeostatic role although in the late
phase of the DSS colitis model (34). The above results collec-
tively suggest a deregulation of the arachidonic acid metabolism–
prostaglandin synthesis pathway in Tpl2 deficient IMFs which
may underlie their defective homeostatic function upon epithe-
lial injury in a mechanism partially mediated by Cox-2.
Exogenous PGE2 Administration Rescues Tpl2
D/D and Tpl2IMF-KO
Mice from Increased Susceptibility to Colitis Restoring Epithelial
Proliferation. The PGE2 pathway is of particular physiological sig-
nificance in humans highlighted by the fact that the PTGER4 gene
encoding the PGE2 receptor EP4 shows strong genetic association
with both forms of IBD (2). To assess in vivo the physiological
significance of Cox-2-PGE2 activation through Tpl2, we treated
Tpl2D/D and WT mice concurrently with DSS and 16,16-dimethyl
PGE2 (dmPGE2), a stable analog of endogenous PGE2, or with
saline as a control. dmPGE2-treated WT mice showed similar
weight loss to that of control WT mice in response to DSS (Fig. 5A),
implying that exogenous dmPGE2 at this dose does not protect from
colitis when the endogenous PGE2 production pathway is intact. By
striking contrast, dmPGE2 administration in Tpl2
D/D mice led to
rescue from the severe weight loss observed in control Tpl2D/D mice,
leading to a clinical response similar to that observed in WT controls
(Fig. 5A) and to a significantly rectified colon length (Fig. 5B).
dmPGE2 administration also rescued Tpl2
D/D mice from the exac-
erbated tissue damage histological score (Fig. 5C), the extensive loss
of crypts, and the widespread ulceration observed in Tpl2D/D controls,
although it had no effect in WT controls (Fig. 5 C and D). No
differences were observed in inflammation score with dmPGE2
treatment (Fig. 5 C and D). Furthermore, measuring BrdU in-
corporation in crypts on experimental day 8 we observed that
dmPGE2 administration in Tpl2
D/D mice led to restored epithelial
proliferation and crypt survival similar to that of WT controls (Fig.
5E) protecting also the epithelium from excessive epithelial de-
pletion (Fig. 5F). Therefore, PGE2 acts as a major mediator
downstream of Tpl2, able to rescue the functional defects ob-
served in the epithelium in its absence. To examine this pathway in
vivo specifically in IMFs we performed additional dmPGE2
administration experiments in Tpl2IMF-KO mice. dmPGE2 rescues
the increased weight loss, tissue damage score, loss of crypts, and
ulceration observed in DSS + saline-treated Tpl2IMF-KO mice (Fig.
6 A–C). dmPGE2 also restores epithelial proliferation (Fig. 6D),
protecting from epithelial depletion (Fig. 6E). These results es-
tablish the physiological significance of the activation of the Tpl2-
Cox-2-PGE2 pathway in IMFs upon epithelial injury. dmPGE2
administration also rescues TLR4−/− mice (20) andMyd88−/− mice
(30) from exacerbated colitis, but not WT controls, rescuing the
specific defects observed in these mice in terms of epithelial pro-
liferation. Thus, the Cox-2-PGE2 pathway mediates the homeo-
static function of innate microflora recognition in the gut. It
remains unknown, however, which cellular pathways underlie this
homeostatic role of innate recognition. Our present results suggest
IMFs as a cellular link between innate recognition and homeo-
static Cox-2-PGE2 expression in the gut.
Intestinal Myofibroblasts Isolated from the Inflamed Ileum of IBD
Patients Show Decreased MAP3K8 Expression. In the inflamed mu-
cosa of IBD patients, α-SMA–expressing mesenchymal cells
show an altered and in some areas expanded distribution in the
Fig. 6. Exogenous dmPGE2 administration rescues the exacerbated DSS
colitis phenotype of Tpl2IMF-KO mice and restores epithelial proliferation and
structure. Concurrently with 2.5% DSS treatment, Tpl2IMF-KO (n = 24) re-
ceived i.p. injections of dmPGE2 every 12 h at a dose of 10 μg/kg of body
weight. Control (ctrl) Tpl2IMF-KO mice (n = 21) were similarly injected with
saline. Data represent three independent experiments. (A) Treatment with
dmPGE2 protects Tpl2
IMF-KO mice from the weight loss observed in control
Tpl2IMF-KO mice. (B) Histopathological analysis on day 8. Treatment with
dmPGE2 protects Tpl2
IMF-KO mice from the extensive tissue damage observed
in control Tpl2IMF-KO mice. No significant differences are observed in in-
flammation score. (C) Treatment with dmPGE2 rescues Tpl2
IMF-KO mice from
the extensive loss of crypts and ulceration observed in control Tpl2IMF-KO
mice on day 8. H&E-stained sections. (Scale bars: 100 μm.) (D) Treatment with
dmPGE2 protects Tpl2
IMF-KO mice from the defective epithelial proliferation
and the death of crypts observed in control Tpl2IMF-KO mice on day 8 as
shown by BrdU incorporation experiments. (Scale bars: 100 μm.) (E) Treat-
ment with dmPGE2 protects Tpl2
IMF-KO mice from the epithelial depletion
observed in control Tpl2IMF-KO mice on day 8 as shown by E-cadherin
immunostaining. Nuclei are stained with DAPI. (Magnification: 200×.) All
data shown represent mean ± SEM. Student t test or Mann–Whitney test
(*P < 0.05; **P < 0.01).
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lamina propria (Fig. 7A), which is indicative of a potentially
active involvement of these populations in disease processes.
Subepithelial IMFs are a major α-SMA+ mesenchymal cell type
in the lamina propria showing high plasticity and a complex or-
igin from several other mesenchymal but also nonmesenchymal
cell types (23). The above analyses performed in mouse models
strongly suggest a cell-specific homeostatic role of the Tpl2
pathway in IMFs. To determine the relevance of this mechanism
to the complex human situation we performed a series of IMF
isolations from healthy and inflamed tissues, ileum and colon,
from patients diagnosed with either Crohn’s disease (n = 9) or
ulcerative colitis (n = 9) undergoing surgery. IMFs isolated from
healthy tissues of colorectal cancer or diverticulosis patients
(n = 5) were used as additional controls. MAP3K8 gene expression
was significantly reduced in IMFs isolated from the inflamed
ileum of IBD patients compared with IMFs isolated from healthy
ileal tissues (Fig. 7B). No significant difference in MAP3K8 ex-
pression was observed in IMFs isolated from the inflamed colon
of IBD patients (SI Appendix, Fig. S15A). Reduced MAP3K8
gene expression in IMFs in the inflamed ileum appears to be
cell-specific because MAP3K8 expression is slightly increased in
peripheral blood mononuclear cells from IBD patients compared
with control subjects (SI Appendix, Fig. S15B). PTGS2 but not
PTGS1 gene expression levels correlate withMAP3K8 expression
in cultured IMFs isolated from the ileum of Crohn’s disease
patients (SI Appendix, Fig. S16A). This correlation is also ob-
served in snap frozen biopsies from IBD patients but not from
healthy control subjects (SI Appendix, Fig. S16B). The mecha-
nistic details of MAP3K8–PTGS2 interaction in human IMFs
need further investigation, however. The down-regulation of
MAP3K8 gene expression in IMFs in the inflamed intestine of
IBD patients underlines the physiological relevance of this cel-
lular and molecular pathway to human disease.
Collectively, our results establish a mechanism in which IMFs
sense the innate signals and the inflammatory milieu formed in
the pericryptal area upon epithelial damage, to activate the Tpl2-
Cox-2-PGE2 pathway which promotes compensatory epithelial
proliferation in the crypts and intestinal homeostasis. Compari-
son of IBD GWAS results with this pathway shows involvement
of five IBD-associated genes functionally connecting MAP3K8
with IL1R1, MAPK1, NFKB1, and PTGER4 genes (Fig. 8).
Discussion
Our results reveal an IMF-specific homeostatic mechanism
which may be highly relevant to human IBD. The MAP3K8 gene
is located in a high linkage disequilibrium region bordered by
two recombination hot spots (SI Appendix, Fig. S1A). The IBD-
associated SNP rs1042058 shows between-study heterogeneity of
odds ratios; thus, it is a genetic marker of this genetic block
rather than a causative variant itself. ENCODE data provide
clues for candidate causative variants in linkage disequilibrium
with rs1042058 (SI Appendix, Fig. S1B). Cis-eQTL analysis per-
formed in the high linkage disequilibrium region around
MAP3K8 revealed one deletion and 13 SNPs whose minor fre-
quency alleles are associated with diminished MAP3K8 expres-
sion in human cells. A subset of these SNPs is localized inside
regulatory elements active in the normal human colonic mucosa
(SI Appendix, Fig. S17). On the other hand, search in current
human genomic variation data revealed at least 12 rare variants
in the MAP3K8 gene (minor allele frequency < 0.01), either
missense, splice, or frameshift variants, which are predicted to
exert a deleterious effect in Tpl2 protein (SI Appendix, Table S3).
Further investigation is required, however, to identify the genetic
variation(s) in the MAP3K8 gene conferring increased risk for
IBD pathogenesis, either as common variants of small effect,
such as eQTLs, or rare variants of large effect. It is also possible
that the effect ofMAP3K8 in IBD risk relies on the accumulation
of small effect variants in multiple genes of the PGE2 production
and sensing pathway as a whole.
The reduced MAP3K8 gene expression we show in IMFs iso-
lated from the ileum of IBD patients may result from the physi-
ological context of these cells in the inflamed intestine but possibly
also from genetic factors such as the above-mentioned MAP3K8
eQTLs and the fact that the CD-associated NOD2 variant
L1007fsinsC impairs MAP3K8 activation in response to muramyl
dipeptide in human cells (35). On the other hand, MAP3K8 ex-
pression in the gut of ulcerative colitis patients from discordant
twin pairs is negatively correlated with Firmicutes of the genus
Peptostreptococcus (36), which are opportunistic pathogens and
markers of dysbiosis in ulcerative colitis (37). In the unaffected
Fig. 7. MAP3K8 is significantly down-regulated in IMFs isolated from the
inflamed ileum of IBD patients. (A) The network of α-SMA+ mesenchymal
cells in the lamina propria is reorganized in the inflamed ileum and colon of
IBD patients. Immunostainings for α-SMA were performed in paraffin sec-
tions of biopsies taken from patients suffering from Crohn’s disease (n = 6)
or ulcerative colitis (n = 3). Nuclei are stained with DAPI. (Magnification:
200×.) (B) IMFs were isolated from healthy and inflamed ileum tissues of IBD
patients and control subjects (n = 9) (see Materials and Methods for clinical
data). Indicative photomicrographs of primary IMF cultures and of H&E-
stained sections of ileal biopsies from these patients are shown. (Magnifi-
cation: 100×.) MAP3K8 gene expression levels were measured by RT-PCR.
Data shown represent mean ± SEM. Mann–Whitney test.
Fig. 8. Schematic representation of the mechanism proposed in the present
study and the relevant genes which are genetically associated with IBD
pathogenesis in humans. Following epithelial injury IMFs sense penetrating
bacteria and the inflammatory milieu generated to activate a Tpl2-ERK-Cox-
2-PGE2–mediated homeostatic pathway and promote compensatory epi-
thelial proliferation in the crypts. Indicated are genes genetically associated
with IBD in recent GWAS (human symbols in parentheses) (2). These genes
includeMAP3K8 encoding Tpl2 kinase, NFKB1 encoding NF-κB1 (p105) which
physically interacts with Tpl2 regulating its function and preventing its
degradation (3), MAPK1 encoding ERK2, IL1R1 encoding IL-1 receptor, and
the PTGER4 gene encoding the PGE2 receptor EP4.
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siblings of the same study, MAP3K8 expression was negatively
correlated with Faecalibacterium prausnitzii (36), a commensal
bacterium with anti-inflammatory function (38). Therefore,
MAP3K8 expression undergoes dynamic regulation in the human
intestine in response to a combination of physiological, genetic,
and microbial stimuli. The complex interconnection of such reg-
ulatory pathways may explain the fact that in our study, differential
expression of MAP3K8 expression was observed in IMFs isolated
from the ileum but not from the colon of IBD patients.
Tpl2 is currently considered a well-established inflammatory
mediator, with significant pharmacological interest for IBD (3). We
have shown a relevant pathogenic implication of Tpl2 in TnfΔARE
mice which spontaneously develop a chronic T-cell–mediated
Crohn’s-like IBD pathology in the ileum (7) without involvement
of epithelial barrier disruption and restoration processes in which
IMFs could play an important homeostatic role. Here we establish
a homeostatic role for Tpl2 in IMFs in the context of epithelial
injury-driven colitis. These contrasting roles suggested for Tpl2 by
different animal models should be considered for effective thera-
peutic manipulation of the Tpl2 pathway in IBD. Of note, contrary
to our results, a recent report indicated a pathogenic role for Tpl2
in DSS-induced colitis (39). This discrepancy could result from the
different genetic background used or from experimental conditions
such as the use of littermate and cohoused mice; the DSS model is
particularly sensitive to these factors because the intestinal micro-
flora is shaped through maternal transfer in a long-term manner
(40) bearing transferrable colitogenic activity in the DSS model
(41). To avoid microflora and genetic confounding, in the present
study we performed our experiments using only large groups of
littermate and cohoused mice as recommended (42, 43), which was
not clarified in the study by Lawrenz et al. (39). In addition, Tpl2
inhibitor administration in DSS-treated C57BL/6 WT mice did not
confer protection, compared with cohoused littermate controls, in
contrast to the result reported by Lawrenz et al. for the same
dosage (39) (SI Appendix, Fig. S18).
The dominant role of IMFs in the maintenance of epithelial
homeostasis, directly linking innate sensing with epithelial pro-
liferation and repair, is a surprising result of the present study.
The exact cellular pathways underlying the homeostatic role of
innate recognition in the gut remain to be identified, although
increasing evidence suggests such a role for stromal cell types. A
homeostatic function in the stroma has been shown for MyD88
(44) and NLRP3 (45). In addition, NLRP6, which also plays a
homeostatic role in the gut, is highly expressed in IMFs (46).
This key role of IMFs in epithelial homeostasis can be explained
by their subepithelial localization and their physiological impli-
cation in mechanisms of epithelial proliferation and differenti-
ation during development (23, 26). IMFs are in close proximity
to the crypts participating in the construction of the stem cell
niche (23, 24) where they secrete growth factors and morphogens
required in developmental processes (25). PGE2 interacts with
Wnt signaling promoting stem cell survival and proliferation in
tissue regeneration processes (47), and PGE2 supplementation is
required for optimal growth of isolated human colonic crypts in
culture (48). The physiological significance of PGE2 and its re-
ceptor PTGER4 in the intestinal epithelium is highlighted by the
successful use of the PTGER4-agonist ONO-4819CD in a recent
promising Phase-II clinical trial that showed histological im-
provement of ulcerative colitis patients refractory to 5-amino-
salicylates (49). We hypothesize that innate stimulation-driven
Tpl2-mediated Cox-2-PGE2 expression in IMFs is part of an
on/off switch mechanism conditionally activated to support crypt
function under emergency conditions enhancing stem/progenitor
cell survival and/or proliferation. Relevantly, a PGE2-expressing
population identified to be mesenchymal stem cells but not
myofibroblasts (50) shows defective repositioning close to crypts
in the rectum of DSS-treated Myd88−/− mice but not altered
Cox-2 expression (30). However, the exact relationship between
this population, intestinal fibroblasts, and myofibroblasts is not
completely clear (51). The interplay between IMFs, other mes-
enchymal cells, and crypt function is an emerging field. Mesen-
chymal-specific genetic tools will be necessary to clarify these
relationships, given the large variability and plasticity of mes-
enchymal populations in the lamina propria (23).
Another aspect of IMF biology is their implication in mech-
anisms promoting or protecting from tumorigenesis. We have
relevantly shown that Tpl2 in IMFs regulates HGF production
and protects from tumorigenesis induced by a protocol com-
bining azoxymethane administration (a genotoxic-carcinogenic
agent) with multiple cycles of DSS treatment (28). This HGF-
mediated function of Tpl2 appears to be specific for the context
of tumorigenesis because no differential expression of HGF is
observed in the colon of Tpl2D/D and Tpl2IMF-KO mice upon
acute DSS-induced epithelial injury at a time point when dif-
ferences in epithelial proliferation are already observed (SI
Appendix, Fig. S19A). Tpl2D/D and Tpl2IMF-KO mice show in-
creased dysplasia but not tumorigenesis following chronic DSS
treatment in a 50-d protocol without azoxymethane adminis-
tration (SI Appendix, Fig. S19 B–E). Increased dysplasia may
result from chronic proliferative responses compensating Sox-
9+ stem/progenitor cell loss occurring upon acute DSS treat-
ment (Fig. 2 E and F), similar to the dysplastic effect of genetic
Sox-9 ablation in epithelial cells (52). Therefore, Tpl2 is re-
quired early upon epithelial damage for intestinal homeostasis
through the mechanisms shown in the present study, and its
absence under conditions of chronic damage confers increased
susceptibility to dysplasia and to mutagenesis-driven HGF-
mediated tumor development.
The Tpl2-Cox-2-PGE2 pathway is of high pharmacological in-
terest for IBD with strategies aiming at either its inhibition as
a means to dampen inflammatory responses [Cox-2, Tpl2 targeting
(3)] or its activation as a means to promote mucosal healing (49,
51) (PGE2 administration). Accumulation of mutations in the
Tpl2-Cox-2-PGE2 axis is predicted here to increase risk for IBD
pathogenesis and to also prevent the effectiveness of therapies
targeting these molecules as inflammatory mediators. The iden-
tification of the exact genetic variants underlying these associa-
tions will be essential for such patient stratification.
Materials and Methods
Generation and Characterization of tpl2 Conditional Knockout Mice and tpl2
Deficient Mice. The conditional map3k8-tpl2 gene targeting strategy is
shown in SI Appendix, Fig. S3A. The gene was isolated from a C57BL/6J
mouse genome Bacterial Artificial Chromosome library (clone RP24-320F20).
In a three-loxP vector containing a neomycin cassette (pEasyFlox) we inser-
ted a 4.3-kb NotI-BamHI and a 3.1-kb XhoI-XhoI gene fragment as 5′- and
3′-homology arms, respectively. A 1.5-kb SalI-XbaI fragment containing the
tpl2 gene exon 4 was inserted between loxP sites 2 and 3. Excision of exon 4
deletes residues 169–254 of the Tpl2 protein and alters the reading frame
for the rest of the transcript also truncating residues 255–467. Residues 169–
467 encode the serine/threonine kinase active site and the kinase activation
segment of Tpl2. The vector was electroporated into C57BL/6J mouse em-
bryonic stem cells. Clones surviving from positive/negative selection were
screened for 5′ and 3′ homologous recombination by Southern blot. One
clone selected was microinjected into C57BL/6 albino blastocysts and trans-
ferred to pseudopregnant females in the transgenic facility of BSRC “Alexander
Fleming.” Chimeric mice bearing germ-line transmission (Tpl2NFL/+) were
bred to C57BL/6J mice. Crossing with EIIa-Cre transgenic mice (53) led to
offspring with loxP1-loxP3 recombination (complete knockout allele,
defloxed, Tpl2D/+) and loxP1-loxP2 recombination (conditional knockout al-
lele without the neomycin cassette, floxed, Tpl2FL/+), which were validated
with Southern blot and selected as colony founders (SI Appendix, Fig. S3B).
Mice on a mixed C57BL/6J-129sv genetic background were generated upon
breeding with 129sv mice. Genotyping primers were loxp3s 5′-GTTT-
TCACCTGACTGCTCCC-3′ and loxp3a 5′-AGCATTTCCAGACCATCACC-3′ (Flox
allele 368 bp, WT 307 bp), and loxp1s 5′-ATGGCTTTGTGGGATTGTTGTTCC-3′
and loxp3a (Deflox allele 653 bp).
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Tpl2D/D mice were born at the expected Mendelian ratio, developed
normally, and were fertile. The efficient inactivation of tpl2 gene was veri-
fied at the mRNA and protein level (SI Appendix, Fig. S3 C and D). Macro-
phages isolated from Tpl2D/Dmice showed defective ERK activation upon LPS
administration and impaired TNF secretion (SI Appendix, Fig. S3 E and F) as
originally observed in Tpl2−/−mice (4). Tpl2D/Dmice were also resistant to the
TNF-dependent LPS/D-galactosamine lethal endotoxic shock similarly to
Tpl2−/−mice (4) (SI Appendix, Fig. S3G). These results establish a new genetic
tool for the study of cell-specific functions of Tpl2 in vivo.
Study Approval. All mice were used in accordance with the guidance of the In-
stitutional Animal Care andUse Committee of BSRC “Alexander Fleming.”Human
studies were approved by the Ethical Committee of Istituto Clinico Humanitas. All
participants were provided with complete information about the study.
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